ATE462424T1 - Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose - Google Patents

Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose

Info

Publication number: ATE462424T1
Authority: AT; Austria
Prior art keywords: nitrosoglutathione; cystic fibrosis; nebulated; therapeutic use; directed
Prior art date: 2000-10-16

Application number

AT01979236T

Other languages

English (en)

Inventor

Benjamin Gaston

Jonathan Stamler

Original Assignee

Univ Duke

Univ Virginia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-16

Filing date

2001-10-15

Publication date

2010-04-15

2001-10-15 Application filed by Univ Duke, Univ Virginia filed Critical Univ Duke

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE462424T1 publication Critical patent/ATE462424T1/de

Links

201000003883 Cystic fibrosis Diseases 0.000 title abstract 2
108010001742 S-Nitrosoglutathione Proteins 0.000 title abstract 2
HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT01979236T 2000-10-16 2001-10-15 Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose ATE462424T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24070800P	2000-10-16	2000-10-16
PCT/US2001/027768 WO2002032418A1 (en)	2000-10-16	2001-10-15	Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis

Publications (1)

Publication Number	Publication Date
ATE462424T1 true ATE462424T1 (de)	2010-04-15

Family

ID=22907617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01979236T ATE462424T1 (de)	2000-10-16	2001-10-15	Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose

Country Status (8)

Country	Link
US (2)	US6723703B2 (de)
EP (1)	EP1333823B1 (de)
JP (1)	JP4194364B2 (de)
AT (1)	ATE462424T1 (de)
AU (2)	AU2002211222B2 (de)
CA (1)	CA2425489C (de)
DE (1)	DE60141703D1 (de)
WO (1)	WO2002032418A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6314956B1 (en)	1999-09-08	2001-11-13	Duke University	Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
US7045152B2 (en) *	1999-09-08	2006-05-16	Duke University	Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US6930125B2 (en) *	2000-01-14	2005-08-16	John F. Hunt	Airway alkalinization as a therapy for airway diseases
AU2002211222B2 (en) *	2000-10-16	2006-02-09	Duke University	Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
US7432301B2 (en) *	2001-08-20	2008-10-07	University Of Virginia Patent Foundation	Use of S-nitrosothiol signaling to treat disordered control of breathing
GB0125222D0 (en) *	2001-10-19	2001-12-12	Barts & London Nhs Trust	Composition for the treatment of microbial infections
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors
US20040110691A1 (en) *	2001-11-13	2004-06-10	Stamler Jonathan S.	Thiol reactive agents as a therapeutic modality
WO2005004884A2 (en) *	2003-07-09	2005-01-20	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Use of nitrite salts for the treatment of cardiovascular conditions
US8518457B2 (en) *	2004-05-11	2013-08-27	Pulmonox Technologies Corporation	Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US7362274B1 (en) *	2004-07-09	2008-04-22	Huan-Cheng Lien	Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060167106A1 (en) *	2004-11-19	2006-07-27	Mei Zhang	Compounds acting at the centrosome
US8557300B2 (en) *	2005-05-19	2013-10-15	University Of Cincinnati	Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP2669269B1 (de)	2005-05-27	2019-05-22	The University of North Carolina At Chapel Hill	Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
WO2007076053A2 (en) *	2005-12-21	2007-07-05	Nitrox, Llc	Stable s-nitrosothiol formulations
PT2068889T (pt)	2006-08-10	2020-01-30	Roy C Levitt	Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
US7717857B2 (en) *	2007-04-25	2010-05-18	Stc.Unm	Diagnosis of P. aeruginosa infection in the lungs of patients
US20090196930A1 (en) *	2007-12-27	2009-08-06	Aires Pharmaceuticals, Inc.	Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
WO2011022652A1 (en)	2009-08-21	2011-02-24	Novan, Inc.	Topical gels
EP2467173B8 (de)	2009-08-21	2019-06-19	Novan, Inc.	Wundverbände, verfahren zu ihrer anwendung und verfahren zu ihrer herstellung
US8591876B2 (en)	2010-12-15	2013-11-26	Novan, Inc.	Methods of decreasing sebum production in the skin
WO2012118819A2 (en)	2011-02-28	2012-09-07	Novan, Inc.	Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
CA3153463A1 (en)	2012-10-29	2014-05-08	The University Of North Carolina At Chapel Hill	Methods and compositions for treating mucosal tissue disorders
EP2956153A4 (de) *	2013-02-15	2017-03-22	Your Energy Systems, LLC	Behandlung von klebsiella-pneumoniae-vermittelten krankheiten mit sich entwickelnder antibakterieller resistenz mithilfe von liposomal formuliertem glutathion
CN110198728A (zh)	2016-11-17	2019-09-03	莱诺翁股份有限公司	用谷胱甘肽组合物治疗呼吸道疾病和感染
CN111615395B (zh)	2017-11-17	2024-08-06	莱诺翁股份有限公司	稳定的抗坏血酸组合物及其使用方法
AT523662B1 (de) *	2020-03-16	2023-07-15	Aurovir Pharma Gmbh	Gold-haltige Mittel zur Behandlung von Lungeninfektionen
KR20240131358A (ko)	2022-01-04	2024-08-30	레노비온, 아이엔씨.	글루타치온 염을 포함하는 수용액

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4900719A (en) *	1988-08-05	1990-02-13	The Ohio State University	Nitrosothiols as hypotensive agents
US5380758A (en) *	1991-03-29	1995-01-10	Brigham And Women's Hospital	S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5728705A (en) *	1993-10-04	1998-03-17	The Trustees Of Columbia University In The City Of New York	Method of inducing vasorelaxation to treat pulmonary hypertension
US5859058A (en) *	1994-07-14	1999-01-12	Glaxo Wellcome Inc.	Nitric oxide synthase inhibitors for inhibiting the production of airway mucas
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6331543B1 (en) *	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) *	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6617355B1 (en)	1997-05-21	2003-09-09	The University Of Virginia Patent Foundation	Treating asthma by preventing and/or accomodating S-nitrosothiol breakdown
DE19919941A1 (de) *	1999-04-30	2000-11-02	Dimitrios Tsikas	S-Nitroso-N-Acyl-L-Cystein-Ester-Derivate als pharmakologische Wirkstoffe und diese Verbindungen enthaltende Arzneimittel
US7045152B2 (en)	1999-09-08	2006-05-16	Duke University	Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US6314956B1 (en) *	1999-09-08	2001-11-13	Duke University	Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
US20020002136A1 (en) *	2000-06-28	2002-01-03	Hebert Rolland F.	Salts of glutathione
AU2002211222B2 (en) *	2000-10-16	2006-02-09	Duke University	Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
US6359182B1 (en)	2000-10-26	2002-03-19	Duke University	C-nitroso compounds and use thereof
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors

2001
- 2001-10-15 AU AU2002211222A patent/AU2002211222B2/en not_active Ceased
- 2001-10-15 WO PCT/US2001/027768 patent/WO2002032418A1/en not_active Ceased
- 2001-10-15 CA CA2425489A patent/CA2425489C/en not_active Expired - Fee Related
- 2001-10-15 AU AU1122202A patent/AU1122202A/xx active Pending
- 2001-10-15 AT AT01979236T patent/ATE462424T1/de not_active IP Right Cessation
- 2001-10-15 DE DE60141703T patent/DE60141703D1/de not_active Expired - Lifetime
- 2001-10-15 EP EP01979236A patent/EP1333823B1/de not_active Expired - Lifetime
- 2001-10-15 US US10/380,763 patent/US6723703B2/en not_active Expired - Lifetime
- 2001-10-15 JP JP2002535656A patent/JP4194364B2/ja not_active Expired - Fee Related
2004
- 2004-02-06 US US10/772,374 patent/US20050131064A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6723703B2 (en)	2004-04-20
CA2425489A1 (en)	2002-04-25
JP4194364B2 (ja)	2008-12-10
AU1122202A (en)	2002-04-29
WO2002032418A1 (en)	2002-04-25
DE60141703D1 (de)	2010-05-12
EP1333823A1 (de)	2003-08-13
EP1333823A4 (de)	2006-03-01
EP1333823B1 (de)	2010-03-31
AU2002211222B2 (en)	2006-02-09
US20050131064A1 (en)	2005-06-16
JP2004511515A (ja)	2004-04-15
US20030212004A1 (en)	2003-11-13
CA2425489C (en)	2011-05-17

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60141703D1 (de)	2010-05-12	Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose
CY1124931T1 (el)	2022-11-25	Αντιμετωπιση της φαινυλκετονουριας με bh4
EE05419B1 (et)	2011-06-15	Asendatud oksasolidinoonid kombineeritud raviks
NO982172L (no)	1998-05-13	Anvendelse av epinastin for behandling av smerter
ATE508735T1 (de)	2011-05-15	Pulmonale verabreichung von aminoglykosiden
UY27175A1 (es)	2002-09-30	Nueva sal succinato de o-desmetil- venlafaxina
DE60124684D1 (de)	2007-01-04	Sulfonamido-substituierte verbrückte bicycloalkylderivative
DK1178958T3 (da)	2004-06-21	N-cyanomethylamider som proteaseinhibitorer
CY1107054T1 (el)	2012-10-24	Ενωσεις διτοσυλικου αλατος κιναζολινης
SE0100901D0 (sv)	2001-03-15	New composition
CY1108610T1 (el)	2014-04-09	Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MXPA04001256A (es)	2004-05-27	Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
ES2179096T3 (es)	2003-01-16	Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
CY1109229T1 (el)	2013-09-04	Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
DE60101265D1 (de)	2003-12-24	Behandlung von augenschmerzen
CY1112753T1 (el)	2016-02-10	Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
CY1108446T1 (el)	2014-04-09	Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
CY1109001T1 (el)	2014-07-02	Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης
DE60101559D1 (de)	2004-01-29	Benutzung von comt-inhibitoren als analgetika
DE60018422D1 (de)	2005-04-07	Typ v pde-hemmer zur behandlung von mukoviszidose
SE0004101D0 (sv)	2000-11-09	New use
EA200300639A1 (ru)	2003-12-25	Применение sarp-1 для лечения и/или предупреждения склеродермии
AP2049A (en)	2009-09-25	Medicament containing activated antithrombin III
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.